Dr. Don S Dizon
@drdonsdizon.bsky.social
Father and Husband, Oncologist, Editor, Writer, Academician, Humanist
Pinned
Dr. Don S Dizon
@drdonsdizon.bsky.social
· Apr 10
Join us for a two-day interactive course on the fundamentals of sexual health after a cancer diagnosis. The course will run from June 25 - 26, with co-chairs @lindabosserman.bsky.social and @drannekatz.bsky.social and additional faculty member @drdonsdizon.bsky.social
mascc.org/annualmeetin...
mascc.org/annualmeetin...
Sexuality is so innately human we need to be able to talk about it for people with cancer. Join me, Linda Bosserman, and @drannekatz.bsky.social to do just that.
And thanks to @cancercaremascc.bsky.social for offering this!
And thanks to @cancercaremascc.bsky.social for offering this!
For people with metastatic PDL1+ TRIPLE NEG BREAST CANCER, Sacituzumab+pembrolizumab (P) significantly increases PFI by ~3m vs chemo+P (a 35% improvement). Whether its meaningful depends on the person offered it and whether it will ultimately improve OS. #ASCENT meetings.asco.org/abstracts-pr... 8/8
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
June 2, 2025 at 10:39 PM
For people with metastatic PDL1+ TRIPLE NEG BREAST CANCER, Sacituzumab+pembrolizumab (P) significantly increases PFI by ~3m vs chemo+P (a 35% improvement). Whether its meaningful depends on the person offered it and whether it will ultimately improve OS. #ASCENT meetings.asco.org/abstracts-pr... 8/8
For people with advanced hormone receptor positive PIK3CA mutated BREAST CANCER, 1st line tx w/ inavolisib|palbociclib|fulvestrant (PF) increased OS over placebo + PF by 7 months- an almost 30% improvement. 30-month overall survival was also improved by 10%. meetings.asco.org/abstracts-pr... 7/8
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
June 2, 2025 at 10:39 PM
For people with advanced hormone receptor positive PIK3CA mutated BREAST CANCER, 1st line tx w/ inavolisib|palbociclib|fulvestrant (PF) increased OS over placebo + PF by 7 months- an almost 30% improvement. 30-month overall survival was also improved by 10%. meetings.asco.org/abstracts-pr... 7/8
Its not a randomized trial, but the results are reassuring. #KCSGBR18-2 www.asco.org/abstracts-pr... 6b/8
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. - ASCO
www.asco.org
June 2, 2025 at 10:39 PM
Its not a randomized trial, but the results are reassuring. #KCSGBR18-2 www.asco.org/abstracts-pr... 6b/8
For people with metastatic triple-positive BREAST CANCER (Hormone and HER2 positive), one trial of 77p reported that ribociclib, trastuzumab, and letrozole resulted in a 61% overall response rate and median progression-free interval of 30 months. 6a/8
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. - ASCO
www.asco.org
June 2, 2025 at 10:39 PM
For people with metastatic triple-positive BREAST CANCER (Hormone and HER2 positive), one trial of 77p reported that ribociclib, trastuzumab, and letrozole resulted in a 61% overall response rate and median progression-free interval of 30 months. 6a/8
Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
June 2, 2025 at 10:39 PM
Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8
In the absence of frank disease progression, for people with hormone-positive BREAST CANCER, the only reason to switch treatment from an aromatase inhibitor (AI) to a selective estrogen receptor degrader (SERD) is if toxicity is making it hard to take the AI. 5a/8
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
June 2, 2025 at 10:39 PM
In the absence of frank disease progression, for people with hormone-positive BREAST CANCER, the only reason to switch treatment from an aromatase inhibitor (AI) to a selective estrogen receptor degrader (SERD) is if toxicity is making it hard to take the AI. 5a/8
Interestingly, the OS benefit was bigger than the Progression Free Interval which was improved by only one month. It also added no additional toxicity to treatment. 4b/8 #ROSELLA ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
June 2, 2025 at 10:39 PM
Interestingly, the OS benefit was bigger than the Progression Free Interval which was improved by only one month. It also added no additional toxicity to treatment. 4b/8 #ROSELLA ascopubs.org/doi/10.1200/...
For people with platinum-resistant recurrent OVARIAN CANCER, a novel drug that targets the glucocorticoid receptor, called Relacorilant, in combination with nAb-paclitaxel improved overall survival (OS) by 5 months over nAb-paclitaxel alone. 4a/8 #ROSELLA
June 2, 2025 at 10:39 PM
For people with platinum-resistant recurrent OVARIAN CANCER, a novel drug that targets the glucocorticoid receptor, called Relacorilant, in combination with nAb-paclitaxel improved overall survival (OS) by 5 months over nAb-paclitaxel alone. 4a/8 #ROSELLA
For people with OVARIAN CANCER, surgery should be done if their gyn onc feels they can have all tumor resected rather than undergoing medical therapy (neo adjuvant chemo) first. That’s been the standard everywhere I’ve worked and the #TRUST trial affirms this. meetings.asco.org/abstracts-pr... 3/8
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
June 2, 2025 at 10:39 PM
For people with OVARIAN CANCER, surgery should be done if their gyn onc feels they can have all tumor resected rather than undergoing medical therapy (neo adjuvant chemo) first. That’s been the standard everywhere I’ve worked and the #TRUST trial affirms this. meetings.asco.org/abstracts-pr... 3/8
PFS (Progression Free Survival) needs to be renamed. People don’t experience “progression”. A cancer may progress at some interval, and that’s what it should be called: PFI. The only survival is whether one is alive or dead- OS (Overall Survival). We need to stop conflating them. 2/8
June 2, 2025 at 10:39 PM
PFS (Progression Free Survival) needs to be renamed. People don’t experience “progression”. A cancer may progress at some interval, and that’s what it should be called: PFI. The only survival is whether one is alive or dead- OS (Overall Survival). We need to stop conflating them. 2/8
Yes, so great to see you
June 1, 2025 at 8:47 PM
Yes, so great to see you
I shared the ASCO stage with Dr Dawn Hershman when we were both awarded a career development award as we were starting our careers. Amazing to share the stage with her again as we are awarded once more at #ASCO25. Truly honored and excited to do so.
May 30, 2025 at 10:24 PM
I shared the ASCO stage with Dr Dawn Hershman when we were both awarded a career development award as we were starting our careers. Amazing to share the stage with her again as we are awarded once more at #ASCO25. Truly honored and excited to do so.
I'm officially Professor of Medicine at @tuftsmedschool.bsky.social
Yowza.
Yowza.
May 21, 2025 at 3:38 AM
I'm officially Professor of Medicine at @tuftsmedschool.bsky.social
Yowza.
Yowza.
I'm proud to be a part of this international community seeking to improve both access and outcomes for people with breast cancer worldwide.
May 18, 2025 at 12:07 PM
I'm proud to be a part of this international community seeking to improve both access and outcomes for people with breast cancer worldwide.
a great 4d in #Munich with @myesmo.bsky.social. Spoke on the importance of sex after cancer & chaired a session on Breast Cancer in Young Women. With @tanjaspanic.bsky.social from #Slovenia my pal Matteo Lambertini from #Italy, Prof Inez Vaz-Luis from #France, and Antigoni Kretsi from #Greece
May 18, 2025 at 12:07 PM
a great 4d in #Munich with @myesmo.bsky.social. Spoke on the importance of sex after cancer & chaired a session on Breast Cancer in Young Women. With @tanjaspanic.bsky.social from #Slovenia my pal Matteo Lambertini from #Italy, Prof Inez Vaz-Luis from #France, and Antigoni Kretsi from #Greece
Reposted by Dr. Don S Dizon
… and Molly is not alone. More than $2.6B of ongoing research has been canceled (with much more this week, at Harvard).
With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷
With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷
All 4 of my NIH research grants are terminated. These were grants on MDR-TB treatment & strategies for supporting adolescents living w/ HIV. This is a massive waste of resources. I am heartbroken for my Harvard team, my partners in Peru, the next generation of scientists & our country. Shame.
May 16, 2025 at 12:05 PM
… and Molly is not alone. More than $2.6B of ongoing research has been canceled (with much more this week, at Harvard).
With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷
With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷
Leaving for #Munich next week for #ESMOBreast25 Excited to catch up w/ colleagues, especially as I renew my practice in breast oncology @tuftsmedicine.bsky.social If you are interested in joining me, we have a pretty great opportunity! Check it out and LMK.
careers.tuftsmedicine.org/us/en/job/R1...
careers.tuftsmedicine.org/us/en/job/R1...
Breast Oncologist in Boston, Massachusetts, 02111-1552 | Physicians and Advanced Practice Clinicians at Tufts Medicine
Apply for Breast Oncologist job with Tufts Medicine in Boston, Massachusetts, 02111-1552. Physicians and Advanced Practice Clinicians at Tufts Medicine
careers.tuftsmedicine.org
May 9, 2025 at 2:22 AM
Leaving for #Munich next week for #ESMOBreast25 Excited to catch up w/ colleagues, especially as I renew my practice in breast oncology @tuftsmedicine.bsky.social If you are interested in joining me, we have a pretty great opportunity! Check it out and LMK.
careers.tuftsmedicine.org/us/en/job/R1...
careers.tuftsmedicine.org/us/en/job/R1...
Reposted by Dr. Don S Dizon
The community engagement session led by @drdonsdizon.bsky.social at #SCHD25 demonstrated impactful outcomes. The work of Dr. Memnun Seven with cancer survivors, Dr. Andrew Sussman's CAB strategies, and Dr. Vida Henderson's media approaches show that authentic partnerships improve results.
April 26, 2025 at 5:20 PM
The community engagement session led by @drdonsdizon.bsky.social at #SCHD25 demonstrated impactful outcomes. The work of Dr. Memnun Seven with cancer survivors, Dr. Andrew Sussman's CAB strategies, and Dr. Vida Henderson's media approaches show that authentic partnerships improve results.
I'm not practicing much but I am who I am because of my very Catholic parents who taught me right from wrong and to care for everybody. I admired Pope Francis. He will be missed in this very turbulent world.
The Catholic world is in mourning after the passing of Pope Francis, sparking questions about who will take on the role as the head of the Vatican.
Who will be the next Head of the Catholic Church after Pope Francis' death?
www.irishstar.com
April 21, 2025 at 9:35 AM
I'm not practicing much but I am who I am because of my very Catholic parents who taught me right from wrong and to care for everybody. I admired Pope Francis. He will be missed in this very turbulent world.
Huge congratulations!!!!
April 14, 2025 at 2:49 PM
Huge congratulations!!!!
Reposted by Dr. Don S Dizon
So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
ASCO Education: The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology
On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new...
ascoeducation.libsyn.com
April 14, 2025 at 2:46 PM
So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...
Sexuality is so innately human we need to be able to talk about it for people with cancer. Join me, Linda Bosserman, and @drannekatz.bsky.social to do just that.
And thanks to @cancercaremascc.bsky.social for offering this!
And thanks to @cancercaremascc.bsky.social for offering this!
Join us for a two-day interactive course on the fundamentals of sexual health after a cancer diagnosis. The course will run from June 25 - 26, with co-chairs @lindabosserman.bsky.social and @drannekatz.bsky.social and additional faculty member @drdonsdizon.bsky.social
mascc.org/annualmeetin...
mascc.org/annualmeetin...
April 10, 2025 at 9:50 AM
Sexuality is so innately human we need to be able to talk about it for people with cancer. Join me, Linda Bosserman, and @drannekatz.bsky.social to do just that.
And thanks to @cancercaremascc.bsky.social for offering this!
And thanks to @cancercaremascc.bsky.social for offering this!